Glenmark Pharmaceuticals shares gained 2 per cent in afternoon trade on Tuesday after the company received a surprise approval from US FDA for Ezetimibe, the generic version of Merck-Schering Plough's cholesterol lowering drug 'Zetia'.According to market analysts, the drug has US sales of $1.8 billion. Ezetimibe may generate $250 million in cash flows for Glenmark during the exclusivity period.At 2.35 pm, shares of the drug maker were trading at Rs 991.60, up 1.93 per cent against their previous close.CLSA has set a target price of Rs 1,060 for the scrip. According to the investment firm, the pharma major is at the cusp of a revival with pick-up in US approvals.For the year ended March 2015, Glenmark Pharmaceuticals registered consolidated net profit of Rs 475.31 crore, down 12.35 per cent against Rs 542.28 crore last year.
About Money99
Parag Patil is a technical analyst and trading system designer with stock excel programmer. I hope the articles and live chart of nse future and mcx on this Website will be as helpful and profitable to you . I try to update and post new articles tips everyday. My motto is to encourage the traders, so that they should able to understand the technique views behind the moment of stocks. I have deeply analyzed with many technical indicator with parameter and added to my amibroker afl. And even taken backtest report which is never being implemented. Any of the analyst expect me. Seeing all this you may understand that my views is more technical than commercial. If you are profited by my views I fill happy.
0 comentários:
Post a Comment